Recent findings suggest that a personalized approach to recommending CPAP machines to patients with obstructive sleep apnea ...

Zepbound functions by targeting hormone receptors related to appetite regulation, specifically glucagon-like peptide-1 and ...

Apnimed has scored another phase 3 knockout. The Massachusetts biotech’s daily pill for obstructive sleep apnea reduced the ...

For the estimated 54 million Americans with obstructive sleep apnea, bedtime isn't refreshing. Their airways are partially blocked during sleep, leading to daytime grogginess and lasting health ...

In today’s Health Alert, obstructive sleep apnea may soon be treated with a simple, once-a-day pill. This first-in-class oral ...

Topline results from a second phase 3 trial of AD109-an investigational oral therapy combining aroxybutynin and ...

A new treatment you may hear about is Zepbound (tirzepatide). In December 2024, Zepbound became the first FDA-approved medicine for treating obstructive sleep apnea.

Around one billion people around the world suffer from obstructive sleep apnea. Although central sleep apnea isn’t as common, it’s more prevalent in those who suffer from other health conditions.

And as of December 20, Eli Lilly’s weight loss drug Zepbound (tirzepetide) has become the first prescription medication FDA-approved to treat obstructive sleep apnea by increasing airflow and ...

However, studies have shown that exercise can help. Sarah Souri, 58, rid herself of obstructive sleep apnea when her CPAP wasn't effective — and her cure was her passion for disco dancing!

Obstructive sleep apnea is where something in your airway, starting from the tongue all the way down to your voice box, blocks your airway and causes obstructive events, restricting your air flow ...

The other kind is central apnea, where your brain is not sending a stimulus to your lungs to take a breath. As an ear, nose and throat doctor, I see more patients with obstructive sleep apnea.